InvestSMART

Osteopore Limited (ASX:OSX)

ALERT: Price-sensitive ASX Announcement for OSX
Current share price for OSX : $0.005 -0.007 (-60.87%)+
Announcement
Release
9 Sep 2025 8:37AM
Price at Release
$0.012
Full Release
download
Summary
Osteopore Limited, a leader in 3D-printed bioresorbable implants, has announced a collaboration with Tan Tock Seng Hospital to co-develop a novel implant for the treatment of avascular necrosis (AVN) at the hip joint. Funded by a SGD 50,000 grant from NHG Health, the initiative is led by Dr. Michael Yam and aims to enhance the outcomes of core decompression in AVN patients. This 12-month collaboration, starting in September 2025, is expected to tap into a market projected to reach USD 10.2 billion by 2030 and could revolutionize treatment by potentially reducing the need for total hip replacements.
Key Points
  • Osteopore Limited collaborates with Tan Tock Seng Hospital to develop a novel implant for avascular necrosis (AVN).
  • The collaboration is led by Dr. Michael Yam and is funded by a SGD 50,000 MedTech grant from NHG Health.
  • AVN is a condition that interrupts blood supply leading to bone tissue necrosis, predominantly affecting the hip joint.
  • Approximately 10% of AVN cases result in total hip replacement.
  • The market for AVN treatment is projected to reach USD 10.2 billion by 2030.
  • The collaboration aims to create a new implant to improve outcomes for core decompression in AVN of the hip.
  • Osteopore's technology involves 3D-printed bioresorbable implants.
  • The collaboration is expected to run for 12 months starting September 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.